To explore the immune response that is associated with CT26 tumor rejection, we combined prophylactic pCT26-5 DNA vaccination with anti-(α)CD4 or αCD8 T-cell depleting antibodies, to delineate the extent to which the observed tumor control is reliant on either T-cell subset (Fig. 2a). Here, DDX53 is linked to neoplasm.